Key Terms: Cesarean section, Colposcopy, Ectopic pregnancy, Hydatiform mole, Interdisciplinary team, Microcephaly, Molar pregnancy.
Definition
For the most part, cancer that strikes during a pregnancy is unrelated to the pregnancy. The exception is choriocarcinoma. This cancer is only found in pregnancy.
Description
Pregnancy can be a joyous time for a woman, but when cancer is diagnosed, a tremendous dilemma can arise, both for the woman and for her health care providers. Cancer is not common in pregnancy, and is rarely the cause of maternal mortality. However, in any pregnancy there are always two patients to consider—the mother and the fetus. When a pregnant woman has cancer, the health of the mother may be pitted against the well-being of the fetus. For women who do not have regular medical visits, pregnancy may be a time for regular prenatal visits. For them, screenings done in pregnancy may serve as an opportunity to detect a hidden cancer.
Interestingly, pregnancy also has some protective effects against breast cancer. Studies have firmly established that early full-time pregnancy helps lower risk for breast cancer for a woman's lifetime.
Choriocarcinoma arises from embryonic fetal tissue called the chorion and chorionic villi. It may be associated with a molar pregnancy, an ectopic pregnancy, and may even develop after the delivery of a normal fetus. It may be referred to as gestational trophoblastic disease (GTD), or gestational trophoblastic tumor. A non-malignant form is a hydatiform mole, but the tissue can become cancerous. Vaginal bleeding and high beta human chorionic gonadotropin (hCG) levels characterize the condition.
Ultrasound is effective in evaluating the mass to establish the presence or absence of a fetus and of a fetal heartbeat. The tissue must be evacuated and sent to pathology for evaluation. If cancerous cells are found, chemotherapy is begun. Chemotherapy has been shown to be extremely effective in treating choriocarcinoma. If left untreated, choriocarcinoma readily metastasizes, or spreads to other organs.
Incidence of GTD rises with maternal age. Women who desire future pregnancies should discuss this as part of the treatment plan to ensure fertility-sparing choices. Some women normally have high hCG levels. If they have some abnormal vaginal bleeding they can be incorrectly diagnosed as having choriocarcinoma if they have a high hCG level without other evidence of a pregnancy. Before undergoing chemotherapy or surgery, women should have a urine pregnancy test done as well, and/or have blood hCG tests done that are able to discriminate between various forms of hCG. Some laboratory hCG tests have a high false-positive rate, and are not designed to screen for hCG that is associated with cancer.
The most common cancers occurring during pregnancy, in descending order are:
Causes
As women delay their childbearing years into their forties and even fifties, an increase of cancer during pregnancy is occurring. This is due to the overlap of childbearing with the usual times of occurrence of certain cancers. The exact cause of most cancers is not yet known. However, estrogen is known to play a role in the development of endometrial and ovarian cancers. Research has shown that smoking increases the risk of developing cervical cancer, as well as other cancers.
Special Concerns
Decisions need to be made about commencing treatment, or delaying treatment until after the pregnancy is finished. Accurate staging of the tumor will be critical. The woman will be asked if the pregnancy is desired. If not, and if the gestation is less than 24 weeks, therapeutic abortion may be considered. Depending on the type and stage of the cancer, a delay in treatment might not affect the mother's prognosis. Fetal lung maturity may be monitored, so that a safe early delivery can be planned. As the fetus nears term, there is a significant decrease in morbidity and mortality for every extra two weeks it remains in utero.
A pregnant woman with cancer has a great need for an interdisciplinary team of experienced practitioners. Oncologists who have experience with treatment during pregnancy may be able to offer more choices for treating the cancer while maintaining a viable pregnancy. Practitioners also need experience in managing the treatment side effects in a safe way for the fetus. For example, corticosteroid use can increase the incidence of cleft palate, and affect maternal glucose intolerance.
Pregnant women should not take any over-the-counter medication, including herbal supplements, without first consulting their obstetrical provider. Medications and supplements considered safe for a non-pregnant woman may have harmful effects on the fetus.
Treatments
Cancer treatment usually involves some combination of surgery, radiation and chemotherapy. During the first trimester, or the first 12 weeks of gestation, the fetus' organs are developing and are very susceptible to teratogenic substances (substances that affect normal fetal development). When treatment is undertaken, it is most commonly in the second trimester, when early fetal development has already taken place.
When contemplating surgery during pregnancy, the risks for both mother and fetus must be considered. Abdominal surgery poses the greatest risk to the pregnancy, however some women can successfully have an ovary removed and still bring a healthy fetus to term. The removal of the ovary needs to take place after the first trimester, once the placenta has taken over the progesterone hormone production of the corpus luteum. General anesthesia is often chosen for surgery. The safest time for surgery is during the second trimester, but the risk of preterm labor, intrauterine growth retardation, and fetal death still exists. Mastectomy is often recommended for the treatment of breast cancer during pregnancy, although breast-conserving surgery may also be an option.
In the first 10 days following conception, radiation may kill the fetus, or may have no effect at all. From 10 days to 14 weeks, a fetus exposed to radiation is at risk for:
From eight weeks until term, the fetus is still at risk for CNS abnormalities and milder forms of microcephaly and mental retardation from radiation. If the mother receives high doses of radiation, intrauterine death may occur. Because of the scarcity of research data, the threshold dose is unknown. Childhood cancers, other cancers later in life, and cancer appearing in later generations are also of concern. Research evaluating the outcome of the children of pregnant women exposed to the atomic bomb in Japan indicates the effects of radiation exposure may show up even five generations later.
When deciding on chemotherapy during pregnancy, several factors are considered:
There are also maternal factors to consider. During pregnancy a woman's blood volume and cardiac output increase, which affects the drugs' concentration levels. If the woman has hyponatremia, this increases the drug concentration in her system. Maternal obesity can affect lipid-soluble drugs. As with radiation, the fetus is most susceptible during the first trimester. Congenital malformations and miscarriage are the most common consequences.
Questions to Ask the Doctor
Fortunately, some chemotherapy drugs seem to be well tolerated by the fetus during the second and third trimesters. These drugs include fluorouracil, doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine, and cyclophosphamide. Even so, the fetus is at risk for low birthweight, miscarriage, and premature birth. Chemotherapy is rarely administered near term. Treatment at this point may be delayed until after delivery, and during this time period the placenta is less able to effectively excrete the drug(s). Drugs that may not harm the fetus in utero may be harmful if consumed via the breast milk. For this reason, breastfeeding is usually discouraged. Methotrexate is known to be teratogenic and so is not given in pregnancy. Daunorubicin and cytarabine are teratogenic in the first trimester. There is not enough known about paclitaxel and pregnancy to consider its use. Of additional concern for the pregnant woman receiving treatment for cancer is the effects on the fetus of any medications that may be used to deal with treatment side effects.
Alternative and Complementary Therapies
A pregnant woman has many limitations on taking medications during pregnancy in order to protect the fetus. Medication that would ordinarily be available to deal with the side effects of cancer treatment may be harmful to the fetus. A helpful resource on the patient's interdisciplinary team is a practitioner with experience in the safe use of complementary therapies for cancer during pregnancy. Mind/body techniques such as guided imagery and meditation can help decrease some of the stress of this time. Acupuncture has been shown to be effective in dealing with the nausea associated with chemotherapy. Support groups can also be a great source of strength and information.
Resources
Books
Runowicz, Carolyn D., Jeanne A. Petrek, and Ted S. Gansler. American Cancer Society: Women and Cancer. New York: Villard Books/Random House, 1999.
Teeley, Peter, and Philip Bashe. The Complete Cancer Survival Guide. New York: Doubleday, 2000.
Periodicals
"Pregnancy Has a Protective Effect Against Breast Cancer." Medical Devices & Surgical Technology Week March 28, 2004: 40.
Rotmensch, S., and L. Cole. "False Diagnosis and Needless Therapy of Presumed Malignant Disease in Women With False-positive Human Chorionic Gonadotropin Concentrations." Lancet February 26, 2000: 712–5.
Organizations
The American Cancer Society. (800) ACS-2345.
Cancer Research Institute. 681 Fifth Ave., New York, NY 10022. (800) 992-2623.
The Gilda Radner Familial Ovarian Cancer Registry. Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263-0001. (800) 682-7426.
National Cancer Institute. Building 31, Room 10A31, 31 Center Dr., MSC 2580, Bethesda, MD 20892-2580. (301) 435-3848.
National Cancer Institute Cancer Trials Web Site.
National Center for Complementary and Alternative Medicine. NCCAM Clearinghouse, PO Box 8218, Silver Spring, MD 20907-8218. (888) 644-6226.
Oncolink at the University of Pennsylvania.
Women's Cancer Network. c/o Gynecologic Cancer Foundation, 401 N. Michigan Ave., Chicago, IL 60611. (312) 644-6610.
—Esther Csapo Rastegari, R.N., B.S.N., Ed.M.; Teresa G. Odle